SYM FINANCIAL Corp Reduces Position in Exelixis, Inc. $EXEL

SYM FINANCIAL Corp decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 10.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,500 shares of the biotechnology company’s stock after selling 739 shares during the quarter. SYM FINANCIAL Corp’s holdings in Exelixis were worth $286,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of EXEL. Nuveen LLC purchased a new stake in shares of Exelixis during the first quarter worth $123,310,000. AQR Capital Management LLC grew its holdings in shares of Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after buying an additional 2,926,884 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after buying an additional 1,596,948 shares in the last quarter. Jupiter Asset Management Ltd. grew its holdings in shares of Exelixis by 233.4% in the first quarter. Jupiter Asset Management Ltd. now owns 1,400,270 shares of the biotechnology company’s stock valued at $51,698,000 after purchasing an additional 980,319 shares during the period. Finally, Pacer Advisors Inc. increased its position in Exelixis by 935.4% during the first quarter. Pacer Advisors Inc. now owns 678,067 shares of the biotechnology company’s stock worth $25,034,000 after purchasing an additional 612,577 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on EXEL shares. Leerink Partners upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a research report on Tuesday, October 21st. Citigroup restated a “market outperform” rating on shares of Exelixis in a research report on Tuesday, October 21st. Barclays started coverage on shares of Exelixis in a research report on Wednesday, September 17th. They set an “equal weight” rating and a $40.00 price objective for the company. Zacks Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Finally, William Blair restated an “outperform” rating on shares of Exelixis in a research report on Tuesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.53.

Exelixis Trading Up 3.3%

Exelixis stock opened at $39.99 on Tuesday. The stock has a market cap of $10.77 billion, a P/E ratio of 19.23, a price-to-earnings-growth ratio of 0.78 and a beta of 0.38. The company has a fifty day simple moving average of $38.72 and a 200-day simple moving average of $40.15. Exelixis, Inc. has a 12-month low of $28.05 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.12. The business had revenue of $568.26 million during the quarter, compared to analysts’ expectations of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The company’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.84 EPS. As a group, sell-side analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.